WAT

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.

Waters took one-and-a-half years to develop its new AI tool, which it says will cut manual drug-testing work performed by scientists by 95%.

WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.

The past six months have been a windfall for Waters Corporation’s shareholders. The company’s stock price has jumped 51.7%, hitting $454.91 per share. This performance may have investors wondering how to approach the situation.

Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate.

WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.

Waters Corporation is all geared up to release its third-quarter earnings next month, and analysts anticipate a double-digit boost in its profitability.

IMU Biosciences and UK Biobank will generate a single-cell immune profiling AI foundational dataset from 80,000 blood samples collected from UK Biobank participants using Ultima Genomics' UG200™ Sequencing Platform and the BD Rhapsody™ Single-Cell Platform…

The limited-edition Key Lime Pie, Strawberry Cupcake, Pineapple Whip and Berry Cobbler flavors deliver everyday indulgence—with zero calories, sugar or sweeteners. SAN FRANCISCO, Oct.